<div id="readability-page-1"><div><p>Hybio Pharmaceutical Co., Ltd. announced private placement of shares for gross proceeds not more than CNY 968,000,000 on September 26, 2025. The shares are issued not more than 30% of total share capital and issue price is not less than 80% of the average price in the 20 trading days before the pricing reference date. The transaction includes participation from not more than 35 investors.</p><p>The transaction has been approved in the 7th Meeting of the Company?s 6th Directorate, and is subject to the approvals of the Company?s Shareholders, the Shenzhen Stock Exchange, and the China Securities Regulatory Commission. The shares cannot be transferred within 6 months from the issuance closing date.</p></div></div>

翰宇藥業

<p>翰宇藥業有限公司宣佈進行私募配股，預計籌集資金最高可達 9.68 億元人民幣。此次發行將不超過總股本的 30%，最低發行價格為過去 20 個交易日平均價格的 80%。該交易已獲得公司第六屆董事會的批准，但仍需獲得股東、深圳證券交易所和中國證券監督管理委員會的進一步批准。發行後，股份將在 6 個月內不可轉讓</p>

翰宇藥業宣佈預計將獲得人民幣 9.68 億元的資金